NBIX Relative Valuation
NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBIX is overvalued; if below, it's undervalued.
Historical Valuation
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 18.12 is considered Undervalued compared with the five-year average of 22.62. The fair price of Neurocrine Biosciences Inc (NBIX) is between 134.39 to 196.80 according to relative valuation methord. Compared to the current price of 133.48 USD , Neurocrine Biosciences Inc is Undervalued By 0.68%.
Relative Value
Fair Zone
134.39-196.80
Current Price：133.48
0.68%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.19
P/B
Median3y
5.67
Median5y
6.65
3.79
FCF Yield
Median3y
3.18
Median5y
2.97
Competitors Valuation Multiple
The average P/S ratio for NBIX's competitors is 8.47, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of 4.57, which is -46.01% above the industry average. Given its robust revenue growth of 11.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Neurocrine Biosciences Inc (NBIX) currently overvalued or undervalued?
What is Neurocrine Biosciences Inc (NBIX) fair value?
How does NBIX's valuation metrics compare to the industry average?
What is the current P/B ratio for Neurocrine Biosciences Inc (NBIX) as of Jul 17 2025?
What is the current FCF Yield for Neurocrine Biosciences Inc (NBIX) as of Jul 17 2025?
What is the current Forward P/E ratio for Neurocrine Biosciences Inc (NBIX) as of Jul 17 2025?